Actelion slaps $160K-plus price tag on new PAH med Uptravi

Actelion thinks it can reach blockbuster heights with new pulmonary arterial hypertension (PAH) treatment Uptravi, approved by the FDA last month and launched earlier this week. And a price tag between $160,000 and $170,000 will certainly help it get there. Don't expect payers to balk at the lofty list price, though, the Swiss biotech's COO, Otto Schwarz, told analysts on a Tuesday call. Uptravi will come cheaper than rivals--including United Therapeutics' ($UTHR) Tyvaso--meaning that payers are unlikely to put up a fight. More from FiercePharma

Read more on